Dalva-Aydemir, S. Et Al. 2019. Toward In Vitro Epigenetic Drug Design for Thyroid Cancer: The Promise of PF-03814735, an Aurora Kinase Inhibitor. OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY , vol.23, no.10 , 486-495.

Dalva-Aydemir, S., AKYERLİ BOYLU, C., Yuksel, S. K., Keskin, H., & Yakicier, M. C., (2019). Toward In Vitro Epigenetic Drug Design for Thyroid Cancer: The Promise of PF-03814735, an Aurora Kinase Inhibitor. OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY , vol.23, no.10, 486-495.

Dalva-Aydemir, Sevim Et Al. "Toward In Vitro Epigenetic Drug Design for Thyroid Cancer: The Promise of PF-03814735, an Aurora Kinase Inhibitor," OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY , vol.23, no.10, 486-495, 2019

Dalva-Aydemir, Sevim Et Al. "Toward In Vitro Epigenetic Drug Design for Thyroid Cancer: The Promise of PF-03814735, an Aurora Kinase Inhibitor." OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY , vol.23, no.10, pp.486-495, 2019

Dalva-Aydemir, S. Et Al. (2019) . "Toward In Vitro Epigenetic Drug Design for Thyroid Cancer: The Promise of PF-03814735, an Aurora Kinase Inhibitor." OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY , vol.23, no.10, pp.486-495.

@article{article, author={Sevim Dalva-Aydemir Et Al. }, title={Toward In Vitro Epigenetic Drug Design for Thyroid Cancer: The Promise of PF-03814735, an Aurora Kinase Inhibitor}, journal={OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY}, year=2019, pages={486-495} }